Quality of Life Assessment in Atypical Parkinsonian Disorders

Size: px
Start display at page:

Download "Quality of Life Assessment in Atypical Parkinsonian Disorders"

Transcription

1 Quality of Life in Atypical Parkinsonian Disorders Quality of Life Assessment in Atypical Parkinsonian Disorders Anette Schrag and Caroline E. Selai INTRODUCTION The atypical parkinsonian disorders are chronic progressive conditions, which not only shorten life expectancy but affect many aspects of patients and their carers lives. No curative treatment for these disorders is available, and management of these patients largely has to concentrate on amelioration of symptoms, such as falls, immobility, autonomic features or dysphagia, activities of daily living and (in)dependence, and patients social and emotional well-being; in short, the improvement of patients quality of life. Assessment of patients with atypical parkinsonism has concentrated on objective measures such as mortality and clinical evaluation of impairment and physical functioning, supplemented by laboratory test results. However, a large literature shows that patients own assessments of their health, their preferences, and their views regarding health often differ significantly from physicians objective assessments (1). Where possible, treatment decisions should focus on health outcomes of value to the individual patient. Scales to measure Hr-QoL, fully psychometrically tested and validated, are now used in a number of clinical and research contexts. Some types of Hr-QoL scale yield information that, combined with economic data, can be used to assess the cost benefit of health interventions and to inform decisions about the allocation of scarce health care resources. There are currently no validated measures to assess Hr-QoL in patients with atypical parkinsonian disorders. This chapter starts with a general overview of some of the conceptual and methodological issues relating to the measurement of subjective health assessment and Hr-QoL. Section two gives an overview of Hr-QoL instruments that have been used in Parkinson s disease (PD) and the impact of PD on Hr-QoL. The third section addresses what is known about the Hr-QoL of patients with atypical parkinsonism, in particular multiple system atrophy (MSA) and progressive supranculear palsy (PSP). The chapter concludes with some comments about future research in this area. HEALTH-RELATED QUALITY OF LIFE: CONCEPTUAL AND METHODOLOGICAL ISSUES What Is Quality of Life? Although the definition of this somewhat elusive term is still occasionally discussed in the literature, there is general consensus on some fundamental points. First, although the phrases quality of From: Current Clinical Neurology: Atypical Parkinsonian Disorders Edited by: I. Litvan Humana Press Inc., Totowa, NJ 277

2 278 Schrag and Selai life, health-related quality of life, and health status are used somewhat interchangeably, there is broad agreement that, in the medical context, Hr-QoL should be regarded as a multidimensional construct (2), comprising physical, psychological, and social well-being. Within these three broad dimensions, most Hr-QoL scales have items on physical health and functioning, activities of daily living, mental health (e.g., perceived stigma, anxiety, depression), social activities, family relationships, and cognitive functioning. Because of these multiple factors, it has been argued that although it may be helpful to derive a summary index of Hr-QoL, the different aspects of Hr-QoL as measured by the scale domains should also be presented separately in order to better understand the precise impact of interventions (3). Second, since quality of life is highly subjective, any appraisal of Hr-QoL should rely, where possible, on the perception of the individual patient. Many groups of patients cannot, however, assess their own Hr-QoL, e.g., those with severe dementia, and there is a growing literature on the use of proxy ratings. Third, no quality of life instrument can comprehensively cover all aspects of Hr-QoL. Although some scales attempt to comprehensively assess all aspects of Hr-QoL, such instruments are often lengthy and burdensome and so are not feasible in clinical practice, particularly where patients have disabling conditions. Therefore, most measures focus on a limited number of specific aspects of Hr-QoL. The choice of instrument will be determined by the precise aim of the study. Finally, in order to provide meaningful data for research and clinical practice, Hr-QoL measures need to be carefully developed and validated and there is now a large literature on the validation and psychometric properties that need to be demonstrated before the scientific community will accept that an instrument has been shown to be appropriately validated. Before considering psychometric testing in more detail, it is useful to consider next why Hr-QoL might be measured. Why Assess Health-Related Quality of Life? Though Hr-QoL measures have been developed for a number of reasons, two basic aspects of health care underlie most of the questions that Hr-QoL appraisals set out to answer: outcome of treatment and cost. As discussed above, Hr-QoL has emerged as an important outcome that incorporates patients views of their health. Also, since no country in the world can afford to do all that it is technically possible to do to improve the health of its citizens, the need has arisen for some system of setting priorities. The assessment of the Hr-QoL of patients with atypical parkinsonian disorders will become increasingly important if and when new drug treatments and other therapies for these disorders are developed. Trials will need to address the benefit of therapeutic interventions and measure change of symptoms in relation to Hr-QoL. HEALTH-RELATED QUALITY OF LIFE MEASURES: DEVELOPMENT AND VALIDATION All clinical assessment measures need to be shown to be valid and reliable. In addition, self-completed measures for patients with a disabling disease need to be short and feasible. Instrument developers must test the psychometric properties of a new instrument, which is a labor-intensive exercise, involving a series of studies to obtain data on the performance of the measure in different situations. For a comprehensive review of the statistical procedures, see Streiner and Norman (4). In brief, validity is how well the instrument measures what it purports to measure. There are various statistical procedures for testing different aspects of an instrument s validity. The terminology is somewhat confusing but Streiner and Norman provide a useful guide to the various types (e.g., face validity, construct validity, criterion validity, concurrent validity, and predictive validity). Reliability assesses whether the same measurement can be obtained on other occasions and concerns the amount of error inherent in any measurement. Two basic tests are the internal consistency of a test, measured by coefficient alpha, and test retest reliability where scores taken on two occasions are compared. Sensi-

3 Quality of Life in Atypical Parkinsonian Disorders 279 tivity or responsiveness to change is concerned with how sensitive the measure is to detecting clinically relevant changes in Hr-QoL. This is important for monitoring benefits of treatment. Newer methods that allow further improvement of scales include Rasch analysis and Item Response Theory, a discussion of which is beyond the scope of this chapter. This psychometric testing has not uniformly been conducted with all instruments, particularly older instruments. Types of Hr-QoL Measures There is no gold standard for measuring Hr-QoL and there is a wide range of instruments available, or in development. The categories of Hr-QoL measures have been comprehensively reviewed elsewhere (5). In brief, generic instruments cover a broad range of Hr-QoL domains in a single instrument. Their chief advantage is in facilitating comparisons among different disease groups. Disease-specific instruments reduce patient burden by including only relevant items for a particular illness but their main disadvantage is the lack of comparability of results with those from other disease groups. Health profiles provide separate scores for each of the dimensions of Hr-QoL, whereas a health index, a type of generic instrument, gives a single summary score, usually from 0 (death) to 1 (perfect health). A further category, developed within the economic tradition, is that of utility measures, which are based on preferences for health states. Preference weighted measures are required when the focus is on society as a whole and the societal allocation of scarce resources. The choice of measure will depend upon the goal of the study. Preference-Based Outcome Measures Preference-based outcome measures are a particular type of measure used in economic analyses, such as cost-utility analyses. Cost-utility analysis is a technique that uses the quality adjusted life year (QALY) as an outcome measure. For its calculation, the QALY requires well-being or Hr-QoL to be expressed as a single index score. The three most commonly used preference measurement techniques are visual analog scales, time trade-off, and standard gamble. A review of the literature on the use of Hr-QoL life data in economic studies is beyond the scope of this chapter, but interested readers can consult a series of chapters on this topic in ref. 6. As treatments for atypical parkinsonisan disorders become available, they will undoubtedly be subject to economic appraisal and robust, prospectively collected Hr-QOL data will be important for the calculation of QALYs and for other economic analyses. Which Outcome Measure to Use? The choice of instrument depends on the purpose of the study. A common recommendation is to include both disease-specific and generic measures in an investigation. The generic measure facilitates comparisons of the target group with the normal population and/or other patient groups whereas the disease-specific instrument provides more sensitivity and is therefore usually more responsive to change in health status. If pharmaco-economic evaluation or a comparison of two or more treatment options is the aim of the study, incorporation of an additional utility measure is recommended. In atypical parkinsonism no disease-specific instruments are available to date but disease-specific instruments for MSA and PSP are currently being developed. HEALTH-RELATED QUALITY OF LIFE IN PARKINSON S DISEASE Health-Related Quality of Life Instruments Used in Parkinson s Disease A number of studies have assessed Hr-QoL in idiopathic PD. The authors of the first of these studies used generic instruments including the Sickness Impact Profile (SIP) (7), the Nottingham Health Profile (NHP) (8), the Medical Outcomes Short Form (SF 36) (9), and EQ-5D (10). These

4 280 Schrag and Selai measures were shown to be valid to varying degrees. However, the older instruments, such as the SIP and the NHP have been criticized for their content and their psychometric properties. For example, the NHP is skewed toward the severe end of disability and worse functional status and is therefore less likely to capture subtle changes in early stages of disease. The questions in the SIP have been felt to be offensive to patients by some (11), and the SF 36 may have limited feasibility and validity in patients with parkinsonism (12). However, the SF 36, a widely used Hr-QoL instrument, which has been translated in several languages and been validated for use in many cultures, enables comparisons across cultures and disease groups. The EQ-5D has also been shown to be valid in patients with PD (12), and its brevity of five questions and a visual analog scale is an advantage in disabled patients. In addition, its summary index yields a utility score that can be used in pharmaco-economic analyses. The EQ-5D has also been translation into many languages. More recently, PD-specific Hr-QoL measures have been developed. Table 1 briefly describes the PD-specific Hr-QoL measures, showing the scale domains. All of the PD-specific instruments have been shown to have good psychometric properties, but only the Parkinson s Disease Questionnaire (PDQ 39; ref. 13) and the Parkinson s Disease Quality of Life Questionnaire (PDQL; ref. 14) have been validated by researchers independent of the developers (15). The PDQ 39 is the most widely used Hr-QoL instrument in Parkinson s disease. It has been translated in several languages, and has been shown to be valid, reliable and sensitive to change. An abbreviated format, the PDQ 8, which has been shown to have comparable validity (16), is also available. Although PDQ 39 has been validated in some cultures, including Britain, the United States, Spain, France, China, and Japan, its validity in other cultures needs to be established. The PDQL is similar to the PDQ 39 in content and format, but includes some questions that are missing in the PDQ 39, e.g., on sexuality. It has been validated in The Netherlands and Britain, but it has not been translated into other languages and no validation studies in other cultures are currently available. Its psychometric properties are less well tested than those of the PDQ 39 and some issues such as self-care, role functions, and close relationships are not addressed (15). The Parkinson s Impact Scale (PIMS) was developed to identify the major problems in patients lives in a clinical setting. It is based on consensus rather than testing in a patient sample and its content validity has been criticized (15). However, it is the only instrument that distinguishes between on and off periods and has been reported to be valid, reliable, and sensitive to change (17). The Parkinson s Disease Quality of Life Scale (PDQUALIF) includes questions on fatigue and driving ability, concentrates on the nonmotor symptoms of Parkinson s disease, and has more emphasis on social functioning than other scales (18). The Parkinson s Disease Symptom Inventory (PDSI; ref. 19) has a larger number of questions (51 items) and asks patients to indicate the frequency as well as the distress caused by each item. There is also a German questionnaire, the ParkinsonLebensqualität (PQL), which has been psychometrically tested in a German population (20). The differences between some of these scales are discussed in an excellent review by Marinus et al. (15). Finally, a number of measures that assess only the psychosocial aspects of Hr-QoL, excluding items relating to physical impairment, have recently been developed and validated (21,22). The choice of instrument in each setting will be guided by the differences between the content of the questionnaires, published data on the psychometric testing, and, if relevant to the study, the availability of translations and cultural adaptation. For specific interventions different aspects of Hr-QoL will be important and as no instrument can be both completely comprehensive and feasible, the selection of the instrument will be based on the particular aim of the study. As discussed above, whereas generic instruments can be used in patients with Parkinson s disease, PD-specific instruments are likely to be more valid, sensitive, and responsive to change.

5 Table 1 Disease-Specific Hr-QoL Measures Developed for Parkinson s Disease PD-Specific Measure Number of Items Domains of Hr-QoL Covered by Scale Reference Parkinson Disease Questionnaire 39 mobility, activities of daily living, emotional well-being, stigma, Peto et al (13) 39-item version (PDQ-39) social support, cognition, communications, bodily discomfort Parkinson Disease Questionnaire 8 mobility, activities of daily living, emotional well-being, stigma, Peto et al (16) 8-item version (PDQ-8) social support, cognition, communications, bodily discomfort Parkinson Disease Quality of Life 37 Parkinsonian symptoms, systemic symptoms, emotional functioning, De Boer et al (14) Questionnaire (PDQL) social functioning Parkinson s Impact Scale (PIMS) 10 Work, finance, leisure, safety, travel, self, feel, family, friend, Schulzer et al (17) sexuality; differentiates between on- and off-states Parkinson s Disease Quality of Life 33 Social/role function, self-image/sexuality, sleep, outlook, physical Welsh et al (18) Scale (PDQUALIF) function, independence, urinary function, global HrQoL Parkinson s Disease Symptom 51 Frequency and distress of symptoms; further analysis on scoring Hogan et al (19) Inventory (PDSI) ongoing Fragebogen Parkinson 44 Depression, physical achievement, leisure, concentration, social Van den Berg, 1998 (20) LebensQualität (PLQ) integration, insecurity, restlessness, activity limitation, anxiety Quality of Life in Atypical Parkinsonian Disorders 281

6 282 Schrag and Selai THE IMPACT OF PARKINSONISM ON HEALTH-RELATED QUALITY OF LIFE Parkinson s Disease The only parkinsonian disorder that has been assessed in detail with regard to Hr-Qol is PD. Studies on Hr-QoL of patients with PD have improved our understanding of subjectively experienced difficulties associated with this disease, and we now have a clearer understanding of what aspects of Hr-QoL are most important to patients with PD. A full review of the expanding Hr-QoL literature in PD is beyond the scope of this chapter. However, it has consistently been found that all areas of Hr-QoL are affected by PD, not merely the physical impairment or functioning (23,25,26). The main areas of impairment in PD are in physical functioning, emotional reactions, social isolation, and energy. Other domains of impairment of Hr-QoL in PD, include bodily discomfort/pain, self-image, cognitive function, communication, sleep, role function, and sexual function (23,25 27). It has also become clear that in PD, it is not primarily disease severity and presence of the symptoms of PD that determine Hr-QoL, but the disability associated with these symptoms and, more than any other factor, the presence and severity of depression (24,25,28). Further symptoms, which have also been found to be highly relevant to Hr-QoL of patients with PD, are postural instability and falls, impaired cognition, and insomnia. Other factors, including motor complications of treatment, may also be associated with poorer Hr-QoL in subgroups of patients, but this association is no longer significant once other important factors such as depression and disability due to parkinsonism are accounted for. Potentially Important Quality-of-Life Issues in Atypical Parkinsonian Disorders A wide range of symptoms are likely to be associated with impaired Hr-QoL in atypical parkinsonian disorders, including the cardinal features of parkinsonism, nonmotor symptoms such as sexual and autonomic dysfunction, postural instability and falls, cognitive impairment, and visual disturbances. Some analogies can usefully be drawn from Hr-QoL studies in PD. The degree of disability in atypical parkinsonism is at least as great as in PD and depression occurs in all atypical parkinsonian disorders (29,30). It is therefore likely that these factors are also important in atypical parkinsonian disorders. However, these are likely not to be the only difficulties encountered by patients with atypical parkinsonism in whom, frequently, many systems are affected. The impact of features such as greater autonomic dysfunction, higher rate of falls, behavioral changes, or cognitive impairment, will depend on the type of atypical parkinsonism. In addition, the shortened life expectancy, greater disability, lack of response to treatment, associated nonmotor features, cognitive impairment, and behavioral disturbances in atypical parkinsonian disorders will all impact on patients subjective evaluation of their Hr-QoL. On the other hand, symptoms that occur less frequently in atypical parkinsonism than in PD, such as tremor, hallucinations, dyskinesias, and motor fluctuations, are likely to be of lesser importance to the Hr-QoL in patients with atypical parkinsonian disorders. All of these symptoms may lead to increased dependence on others, a diminished sense of autonomy and self-image (31), impairment of role functioning, emotional disturbances, fear of social stigma associated with physical symptoms, and impairment of social functioning. Table 2 gives examples of features of atypical parkinsonism, domains of Hr-QoL, which can be affected, and demographic and psycho-social variables, which may influence Hr-QoL in patients with atypical parkinsonism. Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) We have recently undertaken in-depth interviews with patients with MSA and PSP and their carers, and conducted a large survey on issues relevant to patients with atypical parkinsonian disorders, with the aim of developing disease-specific Hr-QoL questionnaires for patients with MSA and PSP. There was considerable overlap in reported areas of health-related quality of life issues relevant to patients with PSP and MSA, but also some differences.

7 Table 2 Examples of Factors Relevant to Hr-Qol in Atypical Parkinsonian Disorders Domains of HR-QoL That May Be Affected Features of Atypical Parkinsonian Disorders Demographic Variables Psychosocial Variables Physical function, e.g., mobility, bodily Motor symptoms Age Personal, e.g., coping discomfort, bladder problems strategies, personal attitudes, expectation of optimism Activites of daily living, e.g., self-care, Speech impairment Gender Social and environmental, communication, difficulties eating, reading e.g., social support, health care difficulties resource circumstances, e.g., family or in nursing home Psychological, e.g., stigma, self-image, Autonomic dysfunction Socioeconomic class depression, isolation, fear of future Social, e.g., family life, social interaction, Visual impairment Area of residence dependence on others Role functioning, e.g., emotional, physical Sexual dysfunction Insomnia Cognitive impairment, including bradyphrenia, executive dysfunction, retrieval difficulties, apraxia, neglect Affect, e.g., depression, anxiety Behavioral disturbances, e.g., apathy, disinhibition Quality of Life in Atypical Parkinsonian Disorders 283

8 284 Schrag and Selai The main presentations of MSA, which include autonomic dysfunction and cerebellar symptoms in addition to parkinsonism, were reflected in our preliminary Hr-QoL interviews. Patients with MSA reported difficulties with bladder and autonomic dysfunction among their most common and severe problems, which were not reported as commonly by patients with PSP, or those with PD (32). Lack of coordination, which was also more commonly reported in MSA patients than in PSP patients, is likely to reflect not only parkinsonism but also cerebellar dysfunction, which also results in difficulty walking and balance problems. The reported items transferring from lying down to sitting or difficulty standing up without support may reflect orthostatic hypotension in addition to bradykinesia. Other issues more often rated as important by patients with MSA such as worrying about the family, worrying about the future, or change of role within the family may reflect the younger age group affected by MSA. Although these issues can also be important to patients with PSP, other items were rated as more important by patients with PSP. Problems commonly reported in PSP but rare in Parkinson s disease or MSA include early postural impairment and falls, visual impairment owing to supranuclear gaze palsy, eyelid apraxia or photophobia, clinically relevant cognitive impairment, personality change, swallowing difficulties, and speech disturbances (33). In addition, patients with PSP may develop neuropsychiatric complications, including apathy, inhibition, and depression (29,30). From the patients point of view, these issues are also particular problems, although apathy and personality change were less problematic from the patients than from the carers point of view (34). In patients with MSA as well as PSP, difficulties beyond those of physical and mental symptoms of the disease were rated as important. Patients in both groups not only reported difficulties in daily activities but patients with MSA reported being anxious and worried about the future, had experienced loss of self-esteem and confidence, felt ignored or that nobody could understand their difficulties. Patients with PSP reported difficulties in showing their emotions, frustration and isolation, difficulties in communication, and worrying about others reactions. Without doubt, the impact on the emotional and social aspects of Hr-QoL goes beyond that of physical impairment and disability in both disorders. Other Parkinsonian Disorders For other atypical parkinsonism such as corticobasal degeneration there are currently no data available on Hr-QoL. However, it is likely that, as in the other atypical parkinsonian disorders, there is considerable overlap of Hr-QoL issues, but that some features specific to this syndrome are also particularly relevant to their Hr-QoL, e.g., loss of hand function owing to alien limb, and impairment of activities of daily living because of apraxia. Other features important to PSP or MSA, such as bladder dysfunction or visual disturbances, are likely to have less impact in this patient group. CARER BURDEN It is not only the lives of patients that are severely affected by the chronic progressive disease course, by decreased life expectancy, and by the multiple consequences of atypical parkinsonian disorders; the lives of each family member and, particularly their carers, are also affected. It is likely that atypical parkinsonian disorders affect carers physical functioning (e.g., caring affecting the carer s own health), emotional well-being (e.g., response to change in role, feelings of hopelessness and depression), and social functioning (limitations on social life), but no studies to date have assessed the different aspects of caregiver burden in these disorders. However, one study investigated the correlates and determinants of carer burden in PSP (35). In this study, the impact of PSP on carers increased with advancing disease severity and disability. Interestingly, this was most pronounced in the first 18 mo after diagnosis, but carer burden plateaued after this initial increase. The presence of affective and behavioral problems such as depression and aggression was associated with greater carer burden, and women reported greater carer burden then men, even when disease severity

9 Quality of Life in Atypical Parkinsonian Disorders 285 and behavioral disturbances were accounted for. The overall degree of carer burden appeared similar to that reported in carers of patients with Alzheimer s disease. CONCLUSION The assessment of Hr-QoL in patients with atypical parkinsonian disorders is important for clinical research, surveys, and clinical trials. Since there is no cure, the management and current treatment of these chronic, disabling disorders is aimed at improving patients subjective Hr-QoL. The impact of these disorders on an individual is complex, comprising multiple aspects of physical, cognitive, emotional, and social functioning. The patient s rating of their own Hr-QoL may vary considerably from their physician s assessment. The valid and reliable assessment of patient-rated health status and Hr-QoL will become even more relevant as treatments for these disorders become available and the benefits of treatment need to be rigorously assessed. Generic Hr-QoL instruments can be used, but their validity and feasibility in patients with atypical parkinsonism is not known. PD-specific Hr-QoL instruments, although incorporating a number of features of relevance to atypical parkinsonism, have not been validated in any of the atypical parkinsonian disorders and are likely to lack some of the salient features. The particular manifestations of each of the atypical parkinsonian disorders, e.g., the specific cognitive impairments in PSP or the autonomic features in MSA together with the features of parkinsonism, are not adequately reflected in any of these instruments. Hr-QoL instruments specifically for patients with MSA and PSP and for their carers are currently being developed. FUTURE RESEARCH Little information is available on the impact of atypical parkinsonism on specific domains of Hr-QoL. Our starting point must be to ask the patients what factors are most important to their Hr-QoL. It is anticipated that, analogous to the clinical presentations, some aspects of Hr-QoL, such as mobility, will be common to all of these disorders, whereas specific aspects will be associated with particular disorders, e.g., bladder function in patients with MSA. Identifying the most important aspect of Hr-QoL in these disorders, from the patient s perspective, will assist in the management of these patients and will inform debate about the provision of health care resources. Finally, but perhaps most importantly, if and when symptomatic treatments for these disorders become available, their efficacy and relevance can be assessed by arguably the most important outcome measure: the effect on patients Hr-QoL as rated by the patients themselves. MAJOR QUESTIONS FOR FUTURE RESEARCH What aspects of Hr-QOL are important in atypical parkinsonian disorders, as judged by the patients themselves? Which instruments are most useful to assess Hr-QoL in atypical parkinsonian disorders? Which areas of Hr-QoL are most affected in each of the atypical parkinsonian disorders and what are the implications for the allocation of health care resources? Which demographic, clinical, and environmental factors have the greatest influence on patients s subjective Hr-QoL? What is the effect of potential symptomatic treatments for atypical parkinsonian disorders on patients Hr-QoL as rated by the patients themselves? REFERENCES 1. Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988;57: Spilker B, Revicki DA. Taxonomy of quality of life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia: Lippincott-Raven, 1996: McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires. New York: Oxford University Press, Streiner,DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development and Use, 2nd ed. Oxford: Oxford Medical Publications, 1995.

10 286 Schrag and Selai 5. Brooks RG. Health Status Measurement: A Perspective on Change. Philadelphia: Macmillan, Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia: Lippincott-Raven, Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19: Hunt SM, McEwen J, McKenna SP. Measuring health stats: a new tool for clinicians and epidemiologists. J Royal Coll Gen Pract 1985;35: Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF 36). I. Conceptual framework and item selection. Med Care 1992;30: EuroQoL Group. EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy 1990;16: Mitchell JD, O Brien MR. Quality of life in motor neurone disease towards a more practical assessment tool? J Neurol Neurosurg Psychiatry. 2003;74: Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D a generic quality of life measure is a useful instrument to measure quality of life in patients with Parkinson s disease. J Neurol Neurosurg Psychiatry 2000;69: Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson s disease. Qual Life Res 1995;4: de Boer AG, Wijker W, Speelman JD, de Haes JC. Quality of life in patients with Parkinson s disease: development of a questionnaire. J Neurol Neurosurg Psychiatry 1996;61: Marinus J, Ramaker C, van Hilten JJ, Stiggelbout AM. Health related quality of life in Parkinson s disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry 2002;72: Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson s disease quality of life questionnaire and its associated measures. J Neurol 1998;245(Suppl 1):S10 S Schulzer M, Mak E, Calne SM. The psychometric properties of the Parkinson s Impact Scale (PIMS) as a measure of quality of life in Parkinson s disease. Parkinsonism Relat Disord 2003;9: Welsh M, McDermott MP, Holloway RG, Plumb S, Pfeiffer R, Hubble J, The Parkinson Study Group development and testing of the Parkinson s Disease Quality of Life Scale. Mov Disord 2003;18: Hogan T, Grimaldi R, Dingemanse J, Martin M, Lyons K, Koller W. The Parkinson s disease symptom inventory (PDSI): a comprehensive and sensitive instrument to measure disease symptoms and treatment side-effects. Parkinsonism Relat Disord 1999;5: Van den Berg M. Leben mit Parkinson: Entwicklung und psychometrische Testung des Fragenbogens PLQ. Neurol Rehabil 1998;4: Marinus J, Visser M, Martinez-Martin P, van Hilten JJ, Stiggelbout AM. Questionnaire for patients with Parkinson s disease: the SCOPA-PS. J Clin Epidemiol 2003;56: Spliethoff-Kamminga NGA, Zwinderman AH, Springer MP, Roos RAC. Psychosocial problems in Parkinson s disease: evaluation of a disease-specific questionnaire. Mov Disord 2003;18: Schrag A, Jahanshahi M, Quinn N. How does Parkinson s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15: Schrag A, Jahanshahi M, Quinn N.What contributes to quality of life in patients with Parkinson s disease? J Neurol Neurosurg Psychiatry 2000;69: Karlsen KH, Larsen JP, Tandberg E, Maland JG. Quality of life measurements in patients with Parkinson s disease: a community-based study. Eur J Neurol 1998;5: Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson s disease. Mov Disord 2000;15: Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson s disease: assessing patient health-related quality of life. Qual Life Res 2000;9: Global Parkinson s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson s disease: results from an international survey. Mov Disord 2002;17: Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996;47: Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson s disease. J Neuropsychiatry Clin Neurosci 2001;13: Fitzsimmons B, Bunting LK. Parkinson s disease quality of life issues. Nurs Clin North Am 1993;28: Fitzpatrick R, Peto V, Jenkinson C, Greenhall R, Hyman N. Health-related quality of life in Parkinson s disease: a study of outpatient clinic attenders. Mov Disord 1997;12: Nath U, Ben-Shlomo Y, Thomson RG, Lees AJ, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003;60: Schrag A, Selai D, Davis J, Lees A, Jahanshahi M, Quinn N. Health-related quality of life in patients with progressive supranuclear palsy (PSP). Mov Disord 2003;18: Uttl B, Santacruz P, Litvan I, Grafman J. Caregiving in progressive supranuclear palsy. Neurology 1998;51:

Q uality of life (QoL) is a multidimensional concept that

Q uality of life (QoL) is a multidimensional concept that PAPER Health related quality of life in Parkinson s disease: a systematic review of disease specific instruments J Marinus, C Ramaker, J J van Hilten, A M Stiggelbout... See end of article for authors

More information

Quality of Life in Patients with Parkinson s Disease

Quality of Life in Patients with Parkinson s Disease Quality of Life in Patients with Parkinson s Disease Seuk Kyung Hong, M.D., Kyung Won Park, M.D., Jae Kwan Cha, M.D., Sang Ho Kim, M.D., Dong Yeol Chun, M.D.*, Chang Kook Yang, M.D.*, Jae Woo Kim, M.D.

More information

What contributes to quality of life in patients with Parkinson s disease?

What contributes to quality of life in patients with Parkinson s disease? 308 Department of Neurology, Institute of Neurology, Queen Square, London WC1N 3BG, UK A Schrag M Jahanshahi N Quinn Correspondence to: Professor NP Quinn n.quinn@ion.ucl.ac.uk Received 2 Sepyember 1999

More information

A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson s Disease

A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson s Disease Volume 12 Number 2 2009 VALUE IN HEALTH A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson s Disease Martine Visser, PhD, 1 Dagmar Verbaan, MSc, 1 Stephanie van Rooden,

More information

A Review of Generic Health Status Measures in Patients With Low Back Pain

A Review of Generic Health Status Measures in Patients With Low Back Pain A Review of Generic Health Status Measures in Patients With Low Back Pain SPINE Volume 25, Number 24, pp 3125 3129 2000, Lippincott Williams & Wilkins, Inc. Jon Lurie, MD, MS Generic health status measures

More information

Measuring symptom change in patients with Parkinson s disease

Measuring symptom change in patients with Parkinson s disease Age and Ageing 2000; 29: 41 45 2000, British Geriatrics Society Measuring symptom change in patients with Parkinson s disease JOHN E. HARRISON, SARAH PRESTON 1,STAVIA B. BLUNT 1 CeNeS Ltd, Compass House,

More information

Health related quality of life in Parkinson s disease: a prospective longitudinal study

Health related quality of life in Parkinson s disease: a prospective longitudinal study 584 Department of Neurology, Central Hospital of Rogaland, Postbox 8100, N-4003 Stavanger, Norway K H Karlsen E Tandberg J P Larsen Department of Psychiatry D Årsland Correspondence to: Professor Jan P

More information

Fatigue, mood disorders and sleep problems in patients with Parkinson's disease Havlikova, Eva

Fatigue, mood disorders and sleep problems in patients with Parkinson's disease Havlikova, Eva University of Groningen Fatigue, mood disorders and sleep problems in patients with Parkinson's disease Havlikova, Eva IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF)

More information

Evaluating the psychometric properties of an e-based version of the 39-item Parkinson s Disease Questionnaire

Evaluating the psychometric properties of an e-based version of the 39-item Parkinson s Disease Questionnaire Morley et al. Health and Quality of Life Outcomes (2015) 13:5 DOI 10.1186/s12955-014-0193-1 SHORT REPORT Open Access Evaluating the psychometric properties of an e-based version of the 39-item Parkinson

More information

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is

More information

Pharmacist intervention in the management of Parkinson s disease: evaluating the pharmacist s intervention at a movement disorders outpatient clinic

Pharmacist intervention in the management of Parkinson s disease: evaluating the pharmacist s intervention at a movement disorders outpatient clinic Correspondence to Akram Shueb, Pharmacy Department, Medicine and Surgery, University of Malta, Msida MSD 2080, Malta; akramshueb@yahoo.com Received 1 December 2011 Accepted 26 April 2012 Pharmacist intervention

More information

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential

More information

Cover Page. The handle holds various files of this Leiden University dissertation.

Cover Page. The handle   holds various files of this Leiden University dissertation. Cover Page The handle http://hdl.handle.net/1887/20183 holds various files of this Leiden University dissertation. Author: Rooden, Stephanie Maria van Title: Clinical patterns in Parkinson s disease Date:

More information

Evaluation of Parkinson s Patients and Primary Care Providers

Evaluation of Parkinson s Patients and Primary Care Providers Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,

More information

Measuring health-related quality of life in persons with dementia DOMS results & recommendations

Measuring health-related quality of life in persons with dementia DOMS results & recommendations Measuring health-related quality of life in persons with dementia DOMS results & recommendations Madeleine King, Siggi Zapart, Jan Sansoni, Nick Marosszeky On behalf of the Dementia Outcomes Measurement

More information

Validation of an Arabic Version of the ORWELL97 Questionnaire in Adults with Obesity

Validation of an Arabic Version of the ORWELL97 Questionnaire in Adults with Obesity Validation of an Arabic Version of the ORWELL97 Questionnaire in Adults with Obesity Leila Itani 1, Simona Calugi 2, Dima Kriedieh 1, Germine El Kassas 1, Dana El Masri 1, Hana Tannir 1, Riccardo Della

More information

The EuroQol and Medical Outcome Survey 36-item shortform

The EuroQol and Medical Outcome Survey 36-item shortform How Do Scores on the EuroQol Relate to Scores on the SF-36 After Stroke? Paul J. Dorman, MD, MRCP; Martin Dennis, MD, FRCP; Peter Sandercock, MD, FRCP; on behalf of the United Kingdom Collaborators in

More information

Profile of Generic and Disease-Specific Health-Related Quality of Life Among Nigerians with Parkinson's Disease

Profile of Generic and Disease-Specific Health-Related Quality of Life Among Nigerians with Parkinson's Disease Profile of Generic and Disease-Specific Health-Related Quality of Life Among Nigerians with Parkinson's Disease Type of Article:I!Jif'Jifll Olaitan Okunoye\ God'spower Asekomeh 2, Mayowa Owolabi 3, Arthur

More information

PARKINSON S DISEASE (PD) is a chronic

PARKINSON S DISEASE (PD) is a chronic Topics in Geriatric Rehabilitation Vol. 24, No. 1, pp. 83 89 Copyright c 2008 Wolters Kluwer Health Lippincott Williams & Wilkins Treating Parkinson s Disease The Impact of Different Care Models on Quality

More information

For more information: Quality of Life. World Health Organization Definition of Health

For more information: Quality of Life. World Health Organization Definition of Health Health-Related Quality of Life - 10 John E. Ware, Jr., PhD, Professor and Chief Measurement Sciences Division, Department of Quantitative Health Sciences University of Massachusetts Medical School, Worcester,

More information

Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson s Disease

Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson s Disease https://doi.org/10.14802/jmd.18022 / J Mov Disord 2018;11(3):133-138 pissn 2005-940X / eissn 2093-4939 ORIGINAL ARTICLE Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson s

More information

Quality of life in Parkinson`s Disease

Quality of life in Parkinson`s Disease , pp.375 381 Quality of life in Parkinson`s Disease Opara JA*, Brola W**, Leonardi M***, Błaszczyk B**** *Academy of Physical Education in Katowice, Poland **District Hospital in Konskie, Poland ***Fondazione

More information

SUMMARY chapter 1 chapter 2

SUMMARY chapter 1 chapter 2 SUMMARY In the introduction of this thesis (chapter 1) the various meanings contributed to the concept of 'dignity' within the field of health care are shortly described. A fundamental distinction can

More information

Models and definitions of quality of life

Models and definitions of quality of life Models and definitions of quality of life PoCoG Quality of Life Webinar 20 th August 2015 Dan Costa (we will commence at 5 past the hour) Does [insert intervention] improve quality of life? What does this

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

Atypical parkinsonism

Atypical parkinsonism Atypical parkinsonism Wassilios Meissner Service de neurologie et CMR atrophie multisystématisée, CHU de Bordeaux Institut des Maladies Neurodégénératives, Université Bordeaux 2, CNRS UMR 5293 Parkinsonism?

More information

Measuring health related quality of life in persons with dementia

Measuring health related quality of life in persons with dementia University of Wollongong Research Online Australian Health Services Research Institute Faculty of Business 2008 Measuring health related quality of life in persons with dementia Madeleine King University

More information

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute Parkinson s Disease 2 nd most common neurodegenerative disorder Peak age at onset is 60 years

More information

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:

More information

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone

More information

The clinical diagnosis of Parkinson s disease rests on

The clinical diagnosis of Parkinson s disease rests on ORIGINAL ARTICLE - NEUROLOGY Non motor symptoms of Parkinson s Diseaseits prevalence across the various stages of Parkinson s disease and its correlation with the severity and duration of the disease Chandrasekaran

More information

Faculty. Joseph Friedman, MD

Faculty. Joseph Friedman, MD Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute

More information

The PD You Don t See: Cognitive and Non-motor Symptoms

The PD You Don t See: Cognitive and Non-motor Symptoms The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Assistant Professor of Neurology and Psychiatry University of Colorado Denver Goals 1) What are the most common non-motor

More information

Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B.

Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. UvA-DARE (Digital Academic Repository) Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. Link to publication Citation for published version (APA): Post, B. (2009). Clinimetrics,

More information

Is EQ-5D a Valid Quality of Life Instrument in Patients With Parkinson s Disease? A Study in Singapore

Is EQ-5D a Valid Quality of Life Instrument in Patients With Parkinson s Disease? A Study in Singapore Original Article 521 Is EQ-5D a Valid Quality of Life Instrument in Patients With Parkinson s Disease? A Study in Singapore Nan Luo, 1 PhD, Serena Low, 2 MBBS, MSc, Puay-Ngoh Lau, 3 BHSc(Nursing), Wing-Lok

More information

MULTI SYSTEM ATROPHY: REPORT OF TWO CASES Dipu Bhuyan 1, Rohit Kr. Chandak 2, Pankaj Kr. Patel 3, Sushant Agarwal 4, Debjanee Phukan 5

MULTI SYSTEM ATROPHY: REPORT OF TWO CASES Dipu Bhuyan 1, Rohit Kr. Chandak 2, Pankaj Kr. Patel 3, Sushant Agarwal 4, Debjanee Phukan 5 MULTI SYSTEM ATROPHY: REPORT OF TWO CASES Dipu Bhuyan 1, Rohit Kr. Chandak 2, Pankaj Kr. Patel 3, Sushant Agarwal 4, Debjanee Phukan 5 HOW TO CITE THIS ARTICLE: Dipu Bhuyan, Rohit Kr. Chandak, Pankaj Kr.

More information

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:

More information

The PD You Don t See: Cognitive and Non-motor Symptoms

The PD You Don t See: Cognitive and Non-motor Symptoms The PD You Don t See: Cognitive and Non-motor Symptoms Benzi M. Kluger, M.D., M.S. Associate Professor of Neurology and Psychiatry Director Movement Disorders Center University of Colorado Denver Goals

More information

Anxiety and Depression Are Better Correlates of Parkinson s Disease Quality of Life Than Apathy

Anxiety and Depression Are Better Correlates of Parkinson s Disease Quality of Life Than Apathy This article addresses the Core Competency of Patient Care and Procedural Skills ARTICLES Anxiety and Depression Are Better Correlates of Parkinson s Disease Quality of Life Than Apathy Jacob D. Jones,

More information

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing

More information

PROMs in dementia care. Dr Sarah Smith. Department of Health Services Research & Policy London School of Hygiene & Tropical Medicine

PROMs in dementia care. Dr Sarah Smith. Department of Health Services Research & Policy London School of Hygiene & Tropical Medicine PROMs in dementia care Dr Sarah Smith Department of Health Services Research & Policy London School of Hygiene & Tropical Medicine This presentation reports independent research commissioned and funded

More information

Non-motor symptoms as a marker of. Michael Samuel

Non-motor symptoms as a marker of. Michael Samuel Non-motor symptoms as a marker of progression in Parkinson s s disease Michael Samuel London, UK 1 Definitions and their problems Non-motor symptoms as a marker of progression Non-motor symptoms (NMS)

More information

Range of neuropsychiatric disturbances in patients with Parkinson s disease

Range of neuropsychiatric disturbances in patients with Parkinson s disease 492 Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital D Aarsland N G Lim C Janvin Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway J P Larsen K Karlsen E Tandberg Departments

More information

The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease.

The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease. Kobe J. Med. Sci., Vol. 56, No. 5, pp. E214-E219, 2010 The Effect of Pramipexole on Depressive Symptoms in Parkinson's Disease. NAOKO YASUI 1, KENJI SEKIGUCHI 1, HIROTOSHI HAMAGUCHI 1, and FUMIO KANDA

More information

Quality of Life at the End of Life:

Quality of Life at the End of Life: Quality of Life at the End of Life: Evaluating the Clinical Utility of the QUAL-EC in Patients with Advanced Cancer 13 th Australian Palliative Care Conference 2015 Melbourne, Australia October 1 st 4

More information

ALLIED TEAM TRAINING FOR PARKINSON

ALLIED TEAM TRAINING FOR PARKINSON ALLIED TEAM TRAINING FOR PARKINSON PSYCHOSOCIAL CHALLENGES IN EARLY STAGE PD Elaine Book, M.S.W. 1 Learning Objectives Examine the role of social work in the provision of psycho-social treatment for individuals

More information

Parkinsonian Disorders with Dementia

Parkinsonian Disorders with Dementia Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University

More information

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non

More information

Palliative Care in Adult Neurology

Palliative Care in Adult Neurology Palliative Care in Adult Neurology Veronica Bruno, MD, MPH University of Calgary, Department of Clinical Neurosciences CNSF 53 rd Congress Halifax, Nova Scotia Learning objectives 1. To understand the

More information

Health Related Quality of Life: Cancer cachexia. Professor Graeme D. Smith Editor Journal of Clinical Nursing CMU,Taiwan August 2017

Health Related Quality of Life: Cancer cachexia. Professor Graeme D. Smith Editor Journal of Clinical Nursing CMU,Taiwan August 2017 Health Related Quality of Life: Cancer cachexia Professor Graeme D. Smith Editor Journal of Clinical Nursing CMU,Taiwan August 2017 Overview to lecture Introduction/Scotland Patient related outcome measures

More information

ALLIED TEAM TRAINING FOR PARKINSON

ALLIED TEAM TRAINING FOR PARKINSON ALLIED TEAM TRAINING FOR PARKINSON PSYCHOSOCIAL CHALLENGES IN MIDDLE STAGE PD Elaine Book, M.S.W. 1 Learning Objectives Discuss common psycho-social challenges in the middle stage of PD for the person

More information

Original Article Development, reliability and validity of the psychosocial adaptation scale for Parkinson s disease in Chinese population

Original Article Development, reliability and validity of the psychosocial adaptation scale for Parkinson s disease in Chinese population Int J Clin Exp Med 2015;8(10):19731-19738 www.ijcem.com /ISSN:1940-5901/IJCEM0014622 Original Article Development, reliability and validity of the psychosocial adaptation scale for Parkinson s disease

More information

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia Measure Description Percentage of patients with dementia for whom there was a documented screening* for behavioral

More information

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Pathways bolt 16/6/06 20:38 Page 1 Pa t h w a y s A PARADIGM FOR DISEASE MANAGEMENT IN Pa r k i n s o n s Disease MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006 Clinical diagnosis Pa r k i n s o n s disease

More information

Impact of insufficient drug efficacy of antiparkinson agents on patient s quality of life: a cross-sectional study

Impact of insufficient drug efficacy of antiparkinson agents on patient s quality of life: a cross-sectional study Tsugawa et al. BMC Neurology (2015) 15:105 DOI 10.1186/s12883-015-0360-y RESEARCH ARTICLE Open Access Impact of insufficient drug efficacy of antiparkinson agents on patient s quality of life: a cross-sectional

More information

Ware NIH Lecture Handouts

Ware NIH Lecture Handouts Health-Related Quality of Life - 11 John E. Ware, Jr., PhD, Professor and Chief Measurement Sciences Division, Department of Quantitative Health Sciences University of Massachusetts Medical School, Worcester,

More information

Spinal cord injury and quality of life: a systematic review of outcome measures

Spinal cord injury and quality of life: a systematic review of outcome measures Systematic review Spinal cord injury and quality of life: a systematic review of outcome measures 37 37 44 Spinal cord injury and quality of life: a systematic review of outcome measures Authors Jefferson

More information

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients

Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and

More information

The Chinese University of Hong Kong The Nethersole School of Nursing. CADENZA Training Programme

The Chinese University of Hong Kong The Nethersole School of Nursing. CADENZA Training Programme The Chinese University of Hong Kong The Nethersole School of Nursing CTP003 Chronic Disease Management and End-of-life Care Web-based Course for Professional Social and Health Care Workers Copyright 2012

More information

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

MAXIMIZING FUNCTION IN PARKINSON S DISEASE 1 MAXIMIZING FUNCTION IN PARKINSON S DISEASE September 13, 2016 End Falls This Falls Conference Jan Goldstein Elman One Step Ahead Mobility Toronto, Ontario Outline An overview of Parkinson s disease (PD):

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

Validation of the Russian version of the Quality of Life-Rheumatoid Arthritis Scale (QOL-RA Scale)

Validation of the Russian version of the Quality of Life-Rheumatoid Arthritis Scale (QOL-RA Scale) Advances in Medical Sciences Vol. 54(1) 2009 pp 27-31 DOI: 10.2478/v10039-009-0012-9 Medical University of Bialystok, Poland Validation of the Russian version of the Quality of Life-Rheumatoid Arthritis

More information

1. Introduction. 1.1 Background to the report

1. Introduction. 1.1 Background to the report 1. Introduction Chronic fatigue syndrome (CFS/ME) is a genuine illness and imposes a substantial burden on the health of the UK population. Improvement of health and social care for people affected by

More information

10th Medicine Review Course st July Prakash Kumar

10th Medicine Review Course st July Prakash Kumar 10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS

More information

Quality of life defined

Quality of life defined Psychometric Properties of Quality of Life and Health Related Quality of Life Assessments in People with Multiple Sclerosis Learmonth, Y. C., Hubbard, E. A., McAuley, E. Motl, R. W. Department of Kinesiology

More information

Quality of Life after. A Critical Illness: A review of the literature

Quality of Life after. A Critical Illness: A review of the literature 1 Quality of Life after A Critical Illness: A review of the literature 1998 2003 by Harriet Adamson BN MAdEd A Thesis submitted in fulfillment of the requirements for the degree Master of Nursing (Honours)

More information

A pan-european study on outcome measures for psychosocial intervention research in dementia

A pan-european study on outcome measures for psychosocial intervention research in dementia A pan-european study on outcome measures for psychosocial intervention research in dementia CHATTAT Rabih, MONIZ-COOK Esme, WOODS Bob, and members of the INTERDEM JPND outcomes working group 26 th Alzheimer

More information

3/5/2014. New Research Initiatives to Improve QoL of Persons with SCI Across the Globe. What Are the SCI International Datasets?

3/5/2014. New Research Initiatives to Improve QoL of Persons with SCI Across the Globe. What Are the SCI International Datasets? New Research Initiatives to Improve QoL of Persons with SCI Across the Globe International SCI Conference: Toward Better Quality of Life Sultan Bin Abdulaziz Humanitarian City Riyadh, KSA Tamara Bushnik,

More information

Table e-1 Commonly used scales and outcome measures

Table e-1 Commonly used scales and outcome measures Table e-1 Commonly used scales and outcome measures Objective outcome Measure Scale range EDSS e14 Disability Divided into 20 half steps ranging from 0 (normal) to 10 (death due to MS) FSs 14 Disability

More information

Differential Diagnosis of Hypokinetic Movement Disorders

Differential Diagnosis of Hypokinetic Movement Disorders Differential Diagnosis of Hypokinetic Movement Disorders Dr Donald Grosset Consultant Neurologist - Honorary Professor Institute of Neurological Sciences - Glasgow University Hypokinetic Parkinson's Disease

More information

15D: Strengths, weaknesses and future development

15D: Strengths, weaknesses and future development 15D: Strengths, weaknesses and future development Harri Sintonen University of Helsinki and FinOHTA Definition of health-related quality of life HRQoL instruments usually try, as does the 15D, to cover

More information

The Assessment in Advanced Dementia (PAINAD) Tool developer: Warden V., Hurley, A.C., Volicer, L. Country of origin: USA

The Assessment in Advanced Dementia (PAINAD) Tool developer: Warden V., Hurley, A.C., Volicer, L. Country of origin: USA Tool: The Assessment in Advanced Dementia (PAINAD) Tool developer: Warden V., Hurley, A.C., Volicer, L. Country of origin: USA Conceptualization Panel rating: 1 Purpose Conceptual basis Item Generation

More information

Depression and Anxiety in Parkinson s Disease. Bill Collins Symposium for Parkinson s Disease 2018 Robert Underwood, Ph.D. Licensed Psychologist

Depression and Anxiety in Parkinson s Disease. Bill Collins Symposium for Parkinson s Disease 2018 Robert Underwood, Ph.D. Licensed Psychologist Depression and Anxiety in Parkinson s Disease Bill Collins Symposium for Parkinson s Disease 2018 Robert Underwood, Ph.D. Licensed Psychologist Today s Discussion Review of Parkinson s Disease and Nonmotor

More information

Non-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors

Non-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors Neurology Asia 2018; 23(4) : 327 331 Non-motor symptoms in Thai Parkinson s disease patients: Prevalence and associated factors Kusuma Samart MD Department of Medicine, Surin Hospital, Surin Province,

More information

DEVELOPMENT OF A NEW PATIENT REPORTED OUTCOME MEASURE FOR MENTAL HEALTH SERVICES

DEVELOPMENT OF A NEW PATIENT REPORTED OUTCOME MEASURE FOR MENTAL HEALTH SERVICES DEVELOPMENT OF A NEW PATIENT REPORTED OUTCOME MEASURE FOR MENTAL HEALTH SERVICES John Brazier Economic Evaluation Policy Research Unit School of Health and Related Research Contact: ReQoL@sheffield.ac.uk

More information

The progression of dementia

The progression of dementia PBO 930022142 NPO 049-191 The progression of dementia Although everyone experiences dementia in their own individual way, it can be helpful to think of the progression of dementia as a series of stages.

More information

Psychometric study of the Persian short-form eight-item Parkinson s disease questionnaire (PDQ-8) to evaluate health related quality of life (HRQoL)

Psychometric study of the Persian short-form eight-item Parkinson s disease questionnaire (PDQ-8) to evaluate health related quality of life (HRQoL) Fereshtehnejad et al. Health and Quality of Life Outcomes 2014, 12:78 RESEARCH Open Access Psychometric study of the Persian short-form eight-item Parkinson s disease questionnaire (PDQ-8) to evaluate

More information

Appendix D- Review of instruments assessing health-related quality of life

Appendix D- Review of instruments assessing health-related quality of life Appendix D- Review of instruments assessing health-related quality of life Excerpted from A review of approaches and instruments for assessing health-related quality of life Tulane University / Horizons

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Dementia: the management of dementia, including the use of antipsychotic medication in older people 1.1 Short title Dementia 2 Background

More information

THE LONG TERM PSYCHOLOGICAL EFFECTS OF DAILY SEDATIVE INTERRUPTION IN CRITICALLY ILL PATIENTS

THE LONG TERM PSYCHOLOGICAL EFFECTS OF DAILY SEDATIVE INTERRUPTION IN CRITICALLY ILL PATIENTS THE LONG TERM PSYCHOLOGICAL EFFECTS OF DAILY SEDATIVE INTERRUPTION IN CRITICALLY ILL PATIENTS John P. Kress, MD, Brian Gehlbach, MD, Maureen Lacy, PhD, Neil Pliskin, PhD, Anne S. Pohlman, RN, MSN, and

More information

Neuropsychiatric Syndromes

Neuropsychiatric Syndromes Neuropsychiatric Syndromes Susan Czapiewski,MD VAHCS December 10, 2015 Dr. Czapiewski has indicated no potential conflict of interest to this presentation. She does intend to discuss the off-label use

More information

Common Forms of Dementia Handout Package

Common Forms of Dementia Handout Package Common Forms of Dementia Handout Package Common Forms of Dementia 1 Learning Objectives As a result of working through this module, you should be better able to: 1. Describe clinical features of 4 major

More information

Non Alzheimer Dementias

Non Alzheimer Dementias Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,

More information

PATIENT REPORTED OUTCOMES

PATIENT REPORTED OUTCOMES Introduction to Clinical Research: A Two-week Intensive Course PATIENT REPORTED OUTCOMES Albert W. Wu, MD, MPH Overview 1. Importance of patient perspective 2. Definitions 3. Key concepts to measure as

More information

White Rose Research Online URL for this paper:

White Rose Research Online URL for this paper: This is a repository copy of Estimating the minimally important difference (MID) of the Diabetes Health Profile-18 (DHP-18) for Type 1 and Type 2 Diabetes Mellitus. White Rose Research Online URL for this

More information

M ovement disorders have a strong impact on patients

M ovement disorders have a strong impact on patients PAPER A novel quality of life instrument for deep brain stimulation in movement disorders A Kuehler, G Henrich, U Schroeder, B Conrad, P Herschbach, A Ceballos-Baumann... See end of article for authors

More information

Reliability and validity of the International Spinal Cord Injury Basic Pain Data Set items as self-report measures

Reliability and validity of the International Spinal Cord Injury Basic Pain Data Set items as self-report measures (2010) 48, 230 238 & 2010 International Society All rights reserved 1362-4393/10 $32.00 www.nature.com/sc ORIGINAL ARTICLE Reliability and validity of the International Injury Basic Pain Data Set items

More information

Psychosocial interventions in neurological palliative care patients and their families

Psychosocial interventions in neurological palliative care patients and their families Psychosocial interventions in neurological palliative care patients and their families Prof. Dr. Maria Wasner (1) Interdisciplinary Center for Palliative Medicine, Ludwig-Maximilians-University, Munich,

More information

World Journal of Pharmaceutical and Life Sciences WJPLS

World Journal of Pharmaceutical and Life Sciences WJPLS wjpls, 2016, Vol. 2, Issue 6, 376-388. Research Article ISSN 2454-2229 Salma et al. WJPLS www.wjpls.org SJIF Impact Factor: 3.347 ROLE STRAIN AND BURDEN AMONG CAREGIVERS OF PARKINSON S DISEASE 1 Salma

More information

Instruments Available for Use in Assessment Center

Instruments Available for Use in Assessment Center Instruments Available for Use in Assessment Center The Assessment Center Instrument Library includes instruments from PROMIS, Neuro-QoL, NIH Toolbox and Health LiTT. All instruments are available for use

More information

ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ²

ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ² ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ² ¹ University of Medicine and Pharmacy Cluj-Napoca ² Clinical Rehabilitation Hospital

More information

MORECare: A framework for conducting research in palliative care

MORECare: A framework for conducting research in palliative care MORECare: A framework for conducting research in palliative care Nancy Preston International Observatory on End of Life Care School of Nursing, Midwifery and Social Work Methods for evaluating service

More information

Psychometric Evaluation of Self-Report Questionnaires - the development of a checklist

Psychometric Evaluation of Self-Report Questionnaires - the development of a checklist pr O C e 49C c, 1-- Le_ 5 e. _ P. ibt_166' (A,-) e-r e.),s IsONI 53 5-6b

More information

P20.2. Characteristics of different types of dementia and challenges for the clinician

P20.2. Characteristics of different types of dementia and challenges for the clinician P20.2. Characteristics of different types of dementia and challenges for the clinician, professor Danish Dementia Research Center Rigshospitalet, University of Copenhagen (Denmark) This project has received

More information

Quality of Life Measurement in Neurodegenerative and Related Conditions

Quality of Life Measurement in Neurodegenerative and Related Conditions Quality of Life Measurement in Neurodegenerative and Related Conditions Quality of Life Measurement in Neurodegenerative and Related Conditions Edited by Crispin Jenkinson University of Oxford Michele

More information

Economic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T

Economic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T Economic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion

More information

Chronic Fatigue Syndrome (CFS) / Myalgic Encephalomyelitis/Encephalopathy (ME)

Chronic Fatigue Syndrome (CFS) / Myalgic Encephalomyelitis/Encephalopathy (ME) Chronic Fatigue Syndrome (CFS) / Myalgic Encephalomyelitis/Encephalopathy (ME) This intervention (and hence this listing of competences) assumes that practitioners are familiar with, and able to deploy,

More information

Session outline. Introduction to dementia Assessment of dementia Management of dementia Follow-up Review

Session outline. Introduction to dementia Assessment of dementia Management of dementia Follow-up Review Dementia 1 Session outline Introduction to dementia Assessment of dementia Management of dementia Follow-up Review 2 Activity 1: Person s story Present a person s story of what it feels like to live with

More information

Cluster 1 Common Mental Health Problems (mild)

Cluster 1 Common Mental Health Problems (mild) Cluster 1 Common Mental Health Problems (mild) You have recently sought help for the first time. You have experienced depression and/or anxiety. This may cause distraction or minor disruption to you as

More information

Prodromal symptoms and early detection of Parkinson s disease in general practice: a nested case-control study

Prodromal symptoms and early detection of Parkinson s disease in general practice: a nested case-control study Family Practice Advance Access published May 28, 2014 Family Practice, 2014, Vol. 00, No. 00, 1 6 doi:10.1093/fampra/cmu025 Prodromal symptoms and early detection of Parkinson s disease in general practice:

More information